From: Joseph Wu <joewu@stanford.edu>
Date: Tue, Feb 15, 2022 at 9:39 PM
Subject: RE: in silico modeling expert
To: Brian Shoichet <bshoichet@gmail.com>
Dear Brian,
I hope all is well. I recently started a startup company using clinical genomics, AI/ML, and patient-specific iPSCs to accelerate drug discovery. I wonder if you know of any graduates in your program or department who may be interested in joining our company. The expertise would be as follow:
1.) Computational ligand screening (e.g. docking) for hit identification
2.) Hit-to-lead optimization for establishing quantitative structure-activity-relationship (QSAR)
3.) Computational protein modeling, e.g. homology modeling.
If yes, please feel free to introduce me to him/her and I’ll be happy to set up a zoom call. Thank you in advance.
Best wishes,
Joe
Joseph C. Wu, MD, PhD
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine & Radiology
Stanford University School of Medicine
265 Campus Drive, Rm G1120B
Stanford, CA 94305-5454
Ph: 650-736-2246; Fax: 650-736-0234
Email: joewu@stanford.edu
Lab: http://wulab.stanford.edu
Stanford CVI: http://med.stanford.edu/cvi
From: Brian Shoichet <bshoichet@gmail.com>
Sent: Wednesday, November 3, 2021 11:19 AM
To: Hao Zhang <zhanghao@stanford.edu>
Cc: Stefan Gahbauer <steffgahbauer@gmail.com>; Joseph Wu <joewu@stanford.edu>
Subject: Re: Mentor team for my career development grant (in collaboration with Stefan)
Hi Hao,
Yes, I'd be willing to do it.
Brian
On Wed, Nov 3, 2021 at 8:06 AM Hao Zhang <zhanghao@stanford.edu> wrote:
Dear Brian,
I hope you are doing well.
In the past few months, Stefan and I have been working together to design novel compounds aiming to eliminate neurological off-target effects in CGS15943, a non-selective adenosine antagonist for antifibrotic therapy.
Stefan and I had many discussions, in which he taught me the strategy for in-silico drug development, including ligand-receptor docking, protein homology prediction, and polarized side-chain design. The new design compound is being synthesized, and we will test the effects soon.
I am writing a career development grant for the American Heart Association. As "in-silico based drug development" takes a major part of my proposal. I wonder if you would like to join my mentor team, responsible for the drug design. Our chemistry department or CRO is responsible for the chemical synthesis with your supervision. I can draft the mentor letter with your approval. Thanks for your consideration.
Best wishes,
Hao
--
Brian Shoichet, Professor, UCSF
latest science from the lab: http://www.bkslab.org/